Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lamivudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 2/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | POLG | P54098 | 3/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamivudine SCHEMBL3444480 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL109675 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12964486 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2305925 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2422788 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2240686 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12996723 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL465678 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2806818 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL13006083 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 58912 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432966-B1 | — | — | None | — | — | US | claimed |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4746907-A1 | METHOD OF TREATMENT OF HIV INFECTION WITH VACCINE | Gilead Sciences, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-119350115-B | Method for recovering beta isomer from CME solution containing beta and alpha isomers | ZHEJIANG INTERNATIONAL STUDIES UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026107341-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026101812-A1 | HIV INTEGRASE INHIBITORS FOR TREATMENT OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-15 | — | — | WO | claimed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| WO-1995012400-A1 | NOVEL ENZYME INHIBITORS, THEIR SYNTHESIS, AND METHODS FOR USE | UAB RESEARCH FOUNDATION (US) | 1995-05-11 | — | — | WO | claimed |
| EP-0565549-B1 | USE OF 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF HEPATITIS B | IAF BIOCHEM INT (CA) | 1995-04-05 | — | — | EP | claimed |
| WO-1994005686-A1 | ANOMERISATION PROCESS | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | claimed |
| US-5204466-A | METHOD AND COMPOSITIONS FOR THE SYNTHESIS OF BCH-189 AND RELATED COMPOUNDS | EMORY UNIVERSITY (US) | 1993-04-20 | — | — | US | claimed |
| EP-0517145-A1 | Crystalline oxathiolane derivatives | GLAXO GROUP LIMITED (GB) | 1992-12-09 | — | — | EP | claimed |
| WO-1992018517-A1 | METHOD OF TREATING OR PREVENTING HEPATITIS B VIRUS | YALE UNIVERSITY (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992011852-A1 | USE OF 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES IN THE TREATMENT OF HEPATITIS B | BIOCHEM PHARMA INC. (CA) | 1992-07-23 | — | — | WO | claimed |
| EP-0494119-A1 | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B | BIOCHEM PHARMA INC. (CA) | 1992-07-08 | — | — | EP | claimed |
| WO-1991017159-A1 | 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES | IAF BIOCHEM INTERNATIONAL INC. (CA) | 1991-11-14 | — | — | WO | claimed |
| WO-1991000867-A1 | 5'-DIPHOSPHOHEXOSE NUCLEOSIDE PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-01-24 | — | — | WO | claimed |